Perspective Therapeutics, Inc.

NYSE American CATX

Perspective Therapeutics, Inc. Price to Sales Ratio (P/S) on January 14, 2025: 641.78

Perspective Therapeutics, Inc. Price to Sales Ratio (P/S) is 641.78 on January 14, 2025, a 11,610.08% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Perspective Therapeutics, Inc. 52-week high Price to Sales Ratio (P/S) is 2,677.43 on October 04, 2024, which is 317.19% above the current Price to Sales Ratio (P/S).
Perspective Therapeutics, Inc. 52-week low Price to Sales Ratio (P/S) is 5.29 on January 17, 2024, which is -99.18% below the current Price to Sales Ratio (P/S).
Perspective Therapeutics, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 566.45.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NYSE American: CATX

Perspective Therapeutics, Inc.

CEO	Mr. Johan M. Spoor
IPO Date	Nov. 10, 2005
Location	United States
Headquarters	350 Hills Street
Employees	116
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.

Key trends

Past 5 years